Related Experiment Video

Updated: Apr 27, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

1.0K

[Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas]

Thibault Brotelle1, Jacques-Olivier Bay1

  • 1Centre Jean-Perrin, Département d'oncologie médicale, 58, rue Montalembert, 63011 Clermont-Ferrand cedex 01, France.

Bulletin Du Cancer
|July 1, 2014
PubMed

Insights

Pazopanib is an angiogenesis inhibitor targeting VEGF, PDGF, and c-KIT receptors. It is recommended for treating metastatic renal cell carcinoma and metastatic soft tissue sarcoma after chemotherapy failure.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Angiogenesis plays a crucial role in renal cell carcinoma (RCC) pathogenesis.
  • Anti-angiogenic therapies, including VEGF and VEGFR inhibitors, are established treatments for metastatic RCC (mRCC).

Purpose of the Study:

  • To review the role of Pazopanib, an angiogenesis inhibitor, in the treatment of mRCC and metastatic soft tissue sarcoma.

Main Methods:

  • Pazopanib targets vascular endothelial growth factor (VEGF) receptor, platelet-derived growth factor (PDGF) receptor, and c-KIT receptor.
  • Clinical application in first- and second-line treatment for mRCC.
  • Approved for metastatic soft tissue sarcoma post-chemotherapy failure.

Main Results:

  • Pazopanib is a recommended treatment option for mRCC, applicable in first-line or after cytokine therapy.
  • Pazopanib has demonstrated efficacy in metastatic soft tissue sarcoma following prior chemotherapy.

Conclusions:

  • Pazopanib is a valuable therapeutic option for patients with mRCC and metastatic soft tissue sarcoma.
  • Targeting angiogenesis remains a key strategy in the management of these advanced cancers.
Keywords:
angiogenesispazopanibrenal cell carcinomasoft tissue sarcomatyrosine kinase inhibitor

More Related Videos

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing06:59

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Published on: May 12, 2023

2.0K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

13.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K